During the 18th International Conference on Malignant Lymphoma (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub was pleased to speak with Juan Pablo Alderuccio, University of Miami, Florida, US. We asked, What do the initial results from the LOTIS-7 (NCT04970901) trial suggest for loncastuximab tesirine plus glofitamab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?

In this interview, Dr Alderuccio discussed preliminary data presented at the 18-ICML from the LOTIS-7 clinical trial, a multicenter study exploring novel combination therapies in relapsed or refractory B-cell lymphomas. The discussion focused on the combination of loncastuximab tesirine plus glofitamab, highlighting initial findings on safety, efficacy, and potential implications for patients with DLBCL. 

This educational resource is independently supported by Sobi. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. 

Hosted on Acast. See acast.com/privacy for more information.